BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an
independent director. Dr. Bhatia was elected to serve a three-year term
ending in 2018.
"Dr. Bhatia is a leading physician scientist and medical researcher who
brings a wealth of expertise to our board," said Jeffrey
Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of
Vertex. "Her extensive experience in the field of biomedical engineering
and in-depth understanding on the use of advanced technologies in
medical research will provide valuable insights to our board and our
company as we advance key research and development programs."
Dr. Bhatia is a physician and engineer and has been a professor at the
Massachusetts Institute of Technology (MIT) since 2005. She currently
serves as the John J. and Dorothy Wilson Professor of Health Sciences at
the MIT Institute for Medical Engineering and Science and Electrical
Engineering and Computer Science (EECS). She also currently serves as a
Biomedical Engineer in the Department of Medicine for Brigham and
Women's Hospital, an investigator for the Howard Hughes Medical
Institute, a member of the Koch Institute for Integrative Cancer
Research at MIT and a member of the Broad Institute. She recently
received the Heinz Award for Technology, the Economy, and Employment
from the Heinz Family Foundation and the Lemelson-MIT Prize for her
dedication to STEM education and to improving human health through
technological innovations. From 1998 to 2005, Dr. Bhatia was a professor
of bioengineering and medicine at the University of California at San
Diego. Dr. Bhatia holds a B.S. in Biomedical Engineering from Brown
University, an M.S. in Mechanical Engineering and Ph.D. in Biomedical
Engineering from MIT, and an M.D. from Harvard Medical School.
"I believe Vertex has a unique opportunity to integrate new medical
technologies into its research and development programs in cystic
fibrosis and other diseases in the years ahead," said Dr. Bhatia. "I
look forward to providing my insights as both a physician and scientist
to Vertex's board at this exciting time."
About Vertex
Vertex is a global biotechnology company that aims to discover, develop
and commercialize innovative medicines so people with serious diseases
can lead better lives. In addition to our clinical development programs
focused on cystic fibrosis, Vertex has more than a dozen ongoing
research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and
development sites and commercial offices in the United
States, Europe, Canada and Australia. For five years in a row, Science magazine
has named Vertex one of its Top Employers in the life sciences. For
additional information and the latest updates from the company, please
visit www.vrtx.com.
(VRTX-GEN)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150618006295/en/
Vertex Pharmaceuticals Incorporated
Investors:
Michael
Partridge, 617-341-6108
or
Media:
Zach Barber,
617-341-6470
MediaInfo@vrtx.com
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
